Roche’ Tarceva Extends Lives of Lung Cancer Patients

Boston (DbTechNo) – There are positive results from a phase 3 study of Tarceva, a lung cancer drug manufactured by Roche.

The study showed that patients given the drug lived longer than those not given it, a plus for sure.

The drug was given to lung cancer patients directly after they finished chemotherapy, and extended the lives of those patients.

The drug is not yet approved by the FDA or EU for use in lung cancer patients, but is approved to treat pancreatic cancer.

With lung cancer reportedly the most common form of cancer worldwide, it will be nice to soon have another weapon with which to fight the disease.

• Share
• Tweet
• "&title=""">